[HTML][HTML] PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
Q Li, J Han, Y Yang, Y Chen - Frontiers in Immunology, 2022 - frontiersin.org
Hepatocellular carcinoma (HCC) has a high prevalence and mortality rate worldwide.
Sorafenib monotherapy has been the standard of first-line treatment for advanced HCC for a …
Sorafenib monotherapy has been the standard of first-line treatment for advanced HCC for a …
[HTML][HTML] Metabolic regulation of immune responses to cancer
J Wißfeld, A Werner, X Yan, N Ten Bosch… - Cancer Biology & …, 2022 - ncbi.nlm.nih.gov
The tumor microenvironment is an ecosystem composed of multiple types of cells, such as
tumor cells, immune cells, and cancer-associated fibroblasts. Cancer cells grow faster than …
tumor cells, immune cells, and cancer-associated fibroblasts. Cancer cells grow faster than …
Inhibition of DNMT1 potentiates antitumor immunity in oral squamous cell carcinoma
Epigenetic alterations, including DNA methylation, play crucial roles in the tumor. Epigenetic
drugs like DNA methyltransferase-1 (DNMT1) inhibitors have been exhibited positive effects …
drugs like DNA methyltransferase-1 (DNMT1) inhibitors have been exhibited positive effects …
[HTML][HTML] Sex-dependent PD-L1/sPD-L1 trafficking in human endothelial cells in response to inflammatory cytokines and VEGF
C Baggio, GE Ramaschi, F Oliviero, R Ramonda… - Biomedicine & …, 2023 - Elsevier
Programmed cell death 1 ligand 1 (PD-L1) expressed in non-immune cells is involved in
immune-mediated tissue damage in the context of inflammatory conditions and tumor …
immune-mediated tissue damage in the context of inflammatory conditions and tumor …
Identification of Cytochrome P450 2E1 as a Novel Target in Glioma and Development of Its Inhibitor as an Anti‐Tumor Agent
G Hu, Y Fang, H Xu, G Wang, R Yang, F Gao… - Advanced …, 2023 - Wiley Online Library
Glioblastoma (GBM) is a devastating inflammation‐related cancer for which novel
therapeutic targets are urgently required. Previous studies of the authors indicate …
therapeutic targets are urgently required. Previous studies of the authors indicate …
Oral reactive capillary hemangiomas induced by SHR-1210 in the treatment of non-small cell lung cancer: a case report and literature review
J Zhou, Q Mao, Y Li, Z Li, H He, Q Chen, C Liu - BMC Oral Health, 2021 - Springer
Background Antibodies to PD-1 and PD-L1 have remarkably improved the overall survival of
many patients with advanced solid tumors. SHR-1210 is an anti-PD-1 monoclonal antibody …
many patients with advanced solid tumors. SHR-1210 is an anti-PD-1 monoclonal antibody …
[HTML][HTML] Repurposing drugs for solid tumor treatment: focus on immune checkpoint inhibitors
Q Liu, L Li, W Qin, T Chao - Cancer Biology & Medicine, 2023 - ncbi.nlm.nih.gov
Cancer remains a significant global health challenge with limited treatment options beyond
systemic therapies, such as chemotherapy, radiotherapy, and molecular targeted therapy …
systemic therapies, such as chemotherapy, radiotherapy, and molecular targeted therapy …
Identification of Notch signaling pathway gene mutations as a prognostic biomarker for bladder cancer
C Xue, X Chen, KX Lin, YG Tong, XH Wang - Future Oncology, 2021 - Future Medicine
Purpose: The authors aimed to identify Notch signaling pathway gene mutations as a
prognostic biomarker for bladder cancer. Methods: First, critical Notch signaling pathway …
prognostic biomarker for bladder cancer. Methods: First, critical Notch signaling pathway …
长链非编码 RNA 调控胃癌转移的研究进展.
王林， 文坤明， 黄声凯， 孙跃民 - Tianjin Medical Journal, 2023 - search.ebscohost.com
胃癌是消化系统常见的癌症, 致死率较高. 肿瘤细胞发生远处转移是导致治疗失败和患者死亡的
主要原因之一. 寻找胃癌转移的治疗靶点, 对于提高患者的生存率意义重大 …
主要原因之一. 寻找胃癌转移的治疗靶点, 对于提高患者的生存率意义重大 …
[PDF][PDF] 肿瘤相关免疫细胞介导 PD-1/PD-L1 抑制剂耐药关联因素的研究进展
王旭， 胡越， 张季辉， 王晓玲 - 河北医学, 2023 - hbyxzzs.cn
肿瘤相关免疫细胞介导PD-1 / PD-L1 抑制剂耐药关联因素的研究进展 Page 1 患者脑神经的保护
作用. 作为神经营养因子家族成员之一,脑源性神经营 养因子(BDNF)对神经元的存活,轴突生长和 …
作用. 作为神经营养因子家族成员之一,脑源性神经营 养因子(BDNF)对神经元的存活,轴突生长和 …
